Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 5/20 | 0.59 |
| ▸ | CHRNA4 | P43681 | 5/20 | 0.59 |
| ▸ | LMNA | P02545 | 1/20 | 0.59 |
| ▸ | PLOD2 | O00469 | 1/20 | 0.56 |
| ▸ | PLOD3 | O60568 | 1/20 | 0.56 |
| ▸ | PLOD1 | Q02809 | 1/20 | 0.56 |
| ▸ | TP53 | P04637 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29442130 | 1.00 | CHRNB2 (0.59) | CHRNB2CHRNA4LMNAPLOD2PLOD3 | |
| SCHEMBL4350327 | 0.98 | LMNA (0.62) | CHRNB2CHRNA4LMNAPLOD2PLOD3 | |
| SCHEMBL28722657 | 0.85 | PLOD2 (0.57) | CHRNB2CHRNA4PLOD2PLOD3PLOD1 | |
| SCHEMBL28139563 | 0.84 | CYP3A4 (0.55) | CHRNB2CHRNA4PLOD2PLOD3PLOD1 | |
| SCHEMBL28288593 | 0.84 | PLOD2 (0.47) | CHRNB2CHRNA4LMNAPLOD2PLOD3 | |
| SCHEMBL2376409 | 0.83 | AKR1C3 (0.57) | CHRNB2CHRNA4PLOD2PLOD3PLOD1 | |
| SCHEMBL11544331 | 0.82 | CHRNB2 (0.76) | CHRNB2CHRNA4CHRNA7 | |
| SCHEMBL29959593 | 0.82 | CHRNB2 (0.76) | CHRNB2CHRNA4CHRNA7 | |
| SCHEMBL161236 | 0.82 | CHRNB2 (0.76) | CHRNB2CHRNA4CHRNA7 | |
| SCHEMBL16437214 | 0.81 | TRPV6 (0.60) | CHRNB2CHRNA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 162 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7442800-B2 | Nucleophilic heterocyclic carbene derivatives of Pd(acac)2 for cross-coupling reactions | PROMERUS LLC (US) | 2008-10-28 | — | — | US | claimed |
| CN-101184711-A | Nucleophilic heterocyclic carbene derivatives of pd(acac)2 for cross-coupling reactions | PROMERUS LLC (US) | 2008-05-21 | — | — | CN | claimed |
| EP-1885669-A1 | NUCLEOPHILIC HETEROCYCLIC CARBENE DERIVATIVES OF PD(ACAC)2 FOR CROSS-COUPLING REACTIONS | Promerus LLC (US) | 2008-02-13 | — | — | EP | claimed |
| US-20060287544-A1 | Nucleophilic heterocyclic carbene derivatives of Pd(acac)2 for cross-coupling reactions | PROMERUS LLC (US) | 2006-12-21 | — | — | US | claimed |
| WO-2006128097-A1 | NUCLEOPHILIC HETEROCYCLIC CARBENE DERIVATIVES OF PD(ACAC)2 FOR CROSS-COUPLING REACTIONS | PROMERUS LLC (US) | 2006-11-30 | — | — | WO | claimed |
| US-12392042-B2 | Alternating current (AC) transition-metal catalysis | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2025-08-19 | — | — | US | disclosed |
| CN-119371410-A | Chromone spiro compound and preparation method and application thereof | 中国药科大学 | 2025-01-28 | — | — | CN | disclosed |
| US-20240327410-A1 | Monoacylglycerol Lipase Modulators | JANSSEN PHARMACEUTICA NV (BE) | 2024-10-03 | — | — | US | disclosed |
| US-12036208-B2 | Methods for treating neurodegenerative disorders | ALZHEON, INC. (US) | 2024-07-16 | — | — | US | disclosed |
| US-11993601-B2 | Monoacylglycerol lipase modulators | JANSSEN PHARMACEUTICA NV | 2024-05-28 | — | — | US | disclosed |
| US-11912708-B2 | Macrocyclic heterocycles and uses thereof | KUMQUAT BIOSCIENCES INC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-20230407492-A1 | ALTERNATING CURRENT (AC) TRANSITION-METAL CATALYSIS | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2023-12-21 | — | — | US | disclosed |
| WO-2005055953-A2 | METHODS OF PREVENTING AND TREATING GASTROINTESTINAL DYSFUNCTION | ADOLOR CORPORATION (US) | 2005-06-23 | — | — | WO | disclosed |
| WO-2005056011-A1 | METHODS OF PREVENTING AND TREATING NON-OPIOID INDUCED GASTROINTESTINAL DYSFUNCTION | ADOLOR CORPORATION (US) | 2005-06-23 | — | — | WO | disclosed |
| US-20050124657-A1 | Administering aryl piperidine compound before surgery to treat gastrointestinal disorders and to relieve stress associated with surgery | MERCK SHARP & DOHME LLC | 2005-06-09 | — | — | US | disclosed |
| WO-2004082623-A2 | SUBSTITUTED PIPERIDINE COMPOUNDS | ADOLOR CORPORATION (US) | 2004-09-30 | — | — | WO | disclosed |
| US-20040186135-A1 | Substituted piperidine compounds | CUBIST PHARMACEUTICALS, INC. | 2004-09-23 | — | — | US | disclosed |
| EP-1354887-A1 | Ligands for metals and improved metal-catalyzed processes based thereon | Massachusetts Insitute of Technology (US) | 2003-10-22 | — | — | EP | disclosed |
| EP-1097158-A2 | LIGANDS FOR METALS AND METAL-CATALYZED PROCESSES | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2001-05-09 | — | — | EP | disclosed |
| WO-2000002887-A2 | LIGANDS FOR METALS AND METAL-CATALYZED PROCESSES | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2000-01-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040186135-A1 | Substituted piperidine compounds | OPRK1, OPRD1, OPRM1 | CHRNB2 274/4885CHRNA4 78/4885LMNA 4262/4885 |
| US-11912708-B2 | Macrocyclic heterocycles and uses thereof | HRAS, KRAS, TP53 | CHRNB2 4663/4885CHRNA4 4859/4885LMNA 2455/4885 |
| US-12036208-B2 | Methods for treating neurodegenerative disorders | NLN, CLN6, SNCA | CHRNB2 67/4885CHRNA4 127/4885LMNA 542/4885 |
| US-20050124657-A1 | Administering aryl piperidine compound before surgery to treat gastrointestinal disorders and to relieve stress associated with surgery | PNMT, VIP, PREP | CHRNB2 3838/4885CHRNA4 2129/4885LMNA 4388/4885 |
| US-11993601-B2 | Monoacylglycerol lipase modulators | MGLL, LPL, PNLIP | CHRNB2 388/4885CHRNA4 459/4885LMNA 1845/4885 |
| US-20060287544-A1 | Nucleophilic heterocyclic carbene derivatives of Pd(acac)2 for cross-coupling reactions | NDC1, DDC, PDCD1LG2 | CHRNB2 1610/4885CHRNA4 2812/4885LMNA 4016/4885 |
| US-20240327410-A1 | Monoacylglycerol Lipase Modulators | MGLL, LPL, PNLIP | CHRNB2 388/4885CHRNA4 459/4885LMNA 1845/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.